SUNPHARMA

STOCK NEWS

Sun Pharmaceutical Industries Ltd declined more than 3% on Friday following reports that the company is preparing a binding offer of nearly $13 billion to acquire Organon & Co.. According to reports, Sun Pharma—India’s largest drugmaker by revenue and market capitalisation—is competing with EQT and Grünenthal for the acquisition. Grünenthal is particularly known for its strong pain management portfolio. Organon’s shares had previously fallen over 19%, after a brief rally in January when news of Sun Pharma’s interest first surfaced. The company currently has a market capitalisation of around $2.4 billion on the NYSE. Sun Pharma, meanwhile, ended Thursday with a market valuation of nearly ₹4.03 lakh crore (approximately $42.8 billion). Recent movements in Organon’s stock have shifted investor attention away from concerns about its debt and slow growth, toward the strength of its portfolio, cash flow generation, and potential restructuring opportunities. Organon has been seen as a takeover target since late last year, particularly after it agreed to sell its JADA post-partum haemorrhage treatment system to Laborie Medical for up to $465 million. This deal signalled a strategic pivot from women’s health devices toward a stronger focus on biopharmaceuticals.